# Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

> **NCT04493060** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04493060
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2023-12-07
- **Final completion:** 2025-06-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493060, "Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04493060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*